<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714010</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO1014</org_study_id>
    <nct_id>NCT02714010</nct_id>
  </id_info>
  <brief_title>EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC</brief_title>
  <official_title>Whole Brain Radiotherapy Concurrent With EGFR-TKI Versus EGFR-TKI Alone in the Treatment of Non-small Cell Lung Cancer Patients With Brain Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center phase III randomized controlled study, designing to access whether the
      efficacy of EGFR-TKI alone on patients with brain metastasis from non-small cell lung cancer
      (NSCLC) harboring EGFR mutant type is not inferior to EGFR-TKI concurrent with whole brain
      radiotherapy (WBRT), the primary end point is intracranial PFS (iPFS), while secondary
      outcomes included overall survival (OS), objective response rate (ORR), evaluation of
      cognitive function, quality of life (QoL) and adverse events.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intracranial PFS (iPFS)</measure>
    <time_frame>up to 41 months</time_frame>
    <description>Compare intracranial PFS (iPFS) of two arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>up to 77 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate (ORR)</measure>
    <time_frame>up to 41 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>cognitive impairment</measure>
    <time_frame>up to 77 months</time_frame>
    <description>questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>quality of life (QoL)</measure>
    <time_frame>up to 77 months</time_frame>
    <description>questionnaire</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">601</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients take EGFR-TKI alone till tumor progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients take EGFR-TKI concurrent with whole brain radiotherapy (WBRT) till tumor progression, WBRT started within the first week of taking TKI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGFR-TKI</intervention_name>
    <description>Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Gefitinib/Tarceva/Icotinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>whole brain radiotherapy</intervention_name>
    <description>30Gy/10F</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>WBRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who was confirmed non-small cell lung cancer (NSCLC) by histology or
             cytology, harboring EGFR mutant type (19 and/or 21 exon mutation).

          -  Patients who was confirmed with asymptomatic, treatment naive brain metastasis (didn't
             receive any treatment after diagnosed with brain metastasis) by MRI, couldn't receive
             operation or stereotactic radiosurgery（SRS）.

          -  Appraisable disease, that is there must be at least one lesion with the longest
             diameter&gt;10mm in brain (by brain MRI).

          -  Adult patients (18 to 75 years old). Eastern Cooperative Oncology Group（ECOG）
             performance status 0 to 2. Life expectancy of at least 12 weeks. Haemoglobin &gt; 10g/dl,
             absolute neutrophil count (ANC) &gt; 1.5 x 10^9/L, platelets &gt; 100 x 10^9/L; total
             bilirubin &lt; 1.5x upper limit of normal (ULN). Alanine aminotransferase（ALT） and
             aspartate aminotransferase（AST）&lt; 1.5x ULN in the absence of liver metastases, or &lt; 5x
             ULN in case of liver metastases. Creatinine clearance &gt; 60ml/min (calculated according
             to Cockcroft-gault formula).

          -  Patients should be contraceptive during the period of the trial.

        Exclusion Criteria:

          -  Patients who had received brain radiotherapy or EGFR-TKI before.

          -  Patients who can't receive WBRT.

          -  Uncontrolled intracranial hypertension after steroid or dehydration therapy.

          -  Patients who take phenytoin, Carbamazepine, Rifampicin, Barbital, or St John's Wort
             which will interfere with the metabolism of TKI.

          -  Patients with interstitial lung disease, significant ocular disease, or serious
             uncontrolled systematic disease.

          -  Patients who can't take oral tablets, with active peptic ulcer diseases.

          -  Pregnancy or breast-feeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>li-kun Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>associate chief physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>li-kun Chen</last_name>
    <phone>13798019964</phone>
    <email>chenlk@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University of cancer center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>li-kun chen, doctor</last_name>
      <phone>13798019964</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2015</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li-kun Chen</investigator_full_name>
    <investigator_title>Associate Professor/Associate chief physician</investigator_title>
  </responsible_party>
  <keyword>EGFR-TKI</keyword>
  <keyword>whole brain radiotherapy</keyword>
  <keyword>brain metastasis</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

